New stroke drug receives $6.6 million for clinical trials
Guest ContributorSeptember 24, 2014
A new drug designed to contain damage resulting from a stroke will go to Phase III clinical trials with a $6.6-million donation from Brain Canada and its matching fund partners. The clinical trials, dubbed FRONTIER, will cost $10 million and will be conducted by
Other News
Events For Leaders in
Science, Tech, Innovation, and Policy
Discuss and learn from those in the know at our virtual and in-person events.
See Upcoming Events
You have 1 free article remaining.
Don't miss out - start your free trial today.
Start your FREE trial Already a member? Log in
By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.